Abstract
Doripenem (DPM) is the newest antimicrobial in the carbapenem class. It is a broad spectrum agent with activity against gram-positive, gram-negative and anaerobic bacteria. in vitro Susceptibility testing has demonstrated potent activity for many drug resistant gram-negative pathogens including some that are resistant to imipenem and meropenem. It appears to be less likely to induce resistance for certain pathogens compared to the other carbapenems. The purpose of this review is to introduce DPM and describe its potential role in managing infections due to multi-drug resistant gram-negative bacteria. This article also reviews recent patents related to the carbapenem class of antimicrobials.
Keywords: Doripenem, carbapenem, pseudomonas, multi-drug resistant, pharmacodynamics
Recent Patents on Anti-Infective Drug Discovery
Title: Doripenem: A New Addition to the Carbapenem Class of Antimicrobials
Volume: 4 Issue: 1
Author(s): Jason J. Schafer, Debra A. Goff and Julie E. Mangino
Affiliation:
Keywords: Doripenem, carbapenem, pseudomonas, multi-drug resistant, pharmacodynamics
Abstract: Doripenem (DPM) is the newest antimicrobial in the carbapenem class. It is a broad spectrum agent with activity against gram-positive, gram-negative and anaerobic bacteria. in vitro Susceptibility testing has demonstrated potent activity for many drug resistant gram-negative pathogens including some that are resistant to imipenem and meropenem. It appears to be less likely to induce resistance for certain pathogens compared to the other carbapenems. The purpose of this review is to introduce DPM and describe its potential role in managing infections due to multi-drug resistant gram-negative bacteria. This article also reviews recent patents related to the carbapenem class of antimicrobials.
Export Options
About this article
Cite this article as:
Schafer J. Jason, Goff A. Debra and Mangino E. Julie, Doripenem: A New Addition to the Carbapenem Class of Antimicrobials, Recent Patents on Anti-Infective Drug Discovery 2009; 4 (1) . https://dx.doi.org/10.2174/157489109787236283
DOI https://dx.doi.org/10.2174/157489109787236283 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry Stem Cell Differentiation Stage Factors and their Role in Triggering Symmetry Breaking Processes during Cancer Development: A Quantum Field Theory Model for Reprogramming Cancer Cells to Healthy Phenotypes
Current Medicinal Chemistry Avocado (Persea americana) Seed as a Source of Bioactive Phytochemicals
Current Pharmaceutical Design Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
Current Drug Metabolism Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies
Current Clinical Pharmacology Prediction of MHC-Peptide Binding: A Systematic and Comprehensive Overview
Current Pharmaceutical Design Diagnoses of Gastrointestinal Cancers After Gastrointestinal Bleeding in Patients Receiving Clopidogrel or Warfarin
Current Drug Safety QSAR Study on MHC Class I A Alleles Based on the Novel Parameters of Amino Acids
Protein & Peptide Letters 21.1 Tesla Magnetic Resonance Imaging Apparatus and Image Interpretation: First Report of a Scientific Advancement
Recent Patents on Medical Imaging Protocatechuic Acid Alkyl Esters: Hydrophobicity As a Determinant Factor for Inhibition of NADPH Oxidase
Current Medicinal Chemistry Small-molecule Antiviral Agents in Ongoing Clinical Trials for COVID-19
Current Drug Targets Annotation of the Human Genome by High-Throughput Sequence Analysis of Naturally Occurring Proteins
Current Proteomics EGFR Mutation Testing in Non-Small Cell Lung Cancer
Current Respiratory Medicine Reviews Statin Treatment Non-adherence and Discontinuation: Clinical Implications and Potential Solutions
Current Pharmaceutical Design Consumption of Cooked Navy Bean Powders Modulate the Canine Fecal and Urine Metabolome
Current Metabolomics Immunotherapy for Conformational Diseases
Current Pharmaceutical Design Determinants of Smoking Cessation Attempts Among HIV-Infected Patients: Results from a Hospital-Based Prospective Cohort
Current HIV Research Anaerobic Bacteria as a Cause of Mycotic Aneurysm of the Aorta: Microbiology and Antimicrobial Therapy
Current Cardiology Reviews The Modulating Effects of Endogenous Substances on Drug Metabolising Enzymes and Implications for Inter-Individual Variability and Quantitative Prediction
Current Drug Metabolism VFP: A Visual Algorithm for Predicting Gene Fusion in RNA-Seq Data
Current Bioinformatics